The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Lipid and polymer nanoparticles for drug delivery to bacterial biofilms
Open accessAbstract
Biofilms are matrix-enclosed communities of bacteria that show increased antibiotic resistance and the capability to evade the immune system. They can cause recalcitrant infections which cannot be cured with classical antibiotic therapy. Drug delivery by lipid or polymer nanoparticles is considered a promising strategy for overcoming biofilm resistance. These particles are able to improve the delivery of antibiotics to the bacterial cells, thereby increasing the efficacy of the treatment. In this review we give an overview of the types of polymer and lipid nanoparticles that have been developed for this purpose. The antimicrobial activity of nanoparticle encapsulated antibiotics compared to the activity of the free antibiotic is discussed in detail. In addition, targeting and triggered drug release strategies to further improve the antimicrobial activity are reviewed. Finally, ample attention is given to advanced microscopy methods that shed light on the behavior of nanoparticles inside biofilms, allowing further optimization of the nanoformulations. Lipid and polymer nanoparticles were found to increase the antimicrobial efficacy in many cases. Strategies such as the use of fusogenic liposomes, targeting of the nanoparticles and triggered release of the antimicrobial agent ensured the delivery of the antimicrobial agent in close proximity of the bacterial cells, maximizing the exposure of the biofilm to the antimicrobial agent. The majority of the discussed papers still present data on the in vitro anti-biofilm activity of nanoformulations, indicating that there is an urgent need for more in vivo studies in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bacterial Biofilms: A Common Cause of Persistent Infections
Costerton, J. W., Stewart, P. S., & Greenberg, E. P. (1999) · Science · doi:10.1126/science.284.5418.1318 · Cited by 12,167 · cited 3×
“[ 16, 17] As a consequence, biofilms can cause devastating chronic infections and are associated with an increased morbidity and mortality.”
Costerton, J. W., Lewandowski, Z., Caldwell, D. E., Korber, D. R., & Lappin-Scott, H. M. (1995) · Annual Review of Microbiology · doi:10.1146/annurev.mi.49.100195.003431 · Cited by 4,544
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Antibiotic resistance of bacterial biofilms
Høiby, N., Bjarnsholt, T., Givskov, M., Molin, S., & Ciofu, O. (2010) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.12.011 · Cited by 3,225
Biofilms as Complex Differentiated Communities
Stoodley, P., Sauer, K., Davies, D. G., & Costerton, J. W. (2002) · Annual Review of Microbiology · doi:10.1146/annurev.micro.56.012302.160705 · Cited by 3,158
Chitosan as antimicrobial agent: applications and mode of action.
Rabea, E. I., Badawy, M. E.-T., Stevens, C. V., Smagghe, G., & Steurbaut, W. (2003) · Biomacromolecules · doi:10.1021/bm034130m · Cited by 3,123
Lewis, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.999-1007.2001 · Cited by 1,980
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
Feng, S.-S. (2006) · Nanomedicine · doi:10.2217/17435889.1.3.297 · Cited by 1,951
Survival strategies of infectious biofilms
Fux, C. A., Costerton, J. W., Stewart, P. S., & Stoodley, P. (2005) · Trends in Microbiology · doi:10.1016/j.tim.2004.11.010 · Cited by 1,812
Cited by
Targeting microbial biofilms: current and prospective therapeutic strategies
Koo, H., Allan, R. N., Howlin, R. P., Stoodley, P., & Hall-Stoodley, L. (2017) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.99 · Cited by 1,800
Nanomaterial-based therapeutics for antibiotic-resistant bacterial infections
Makabenta, J. M. V., Nabawy, A., Li, C.-H., Schmidt-Malan, S., Patel, R., & Rotello, V. M. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0420-1 · Cited by 1,397
Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control
Liu, Y., Shi, L., Su, L., van der Mei, H. C., Jutte, P. C., Ren, Y., & Busscher, H. J. (2019) · Chemical Society Reviews · doi:10.1039/c7cs00807d · Cited by 737
Nanoparticle–Biofilm Interactions: The Role of the EPS Matrix
Fulaz, S., Vitale, S., Quinn, L., & Casey, E. (2019) · Trends in Microbiology · doi:10.1016/j.tim.2019.07.004 · Cited by 562
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Prospects of using nanotechnology for food preservation, safety, and security
Bajpai, V. K., Kamle, M., Shukla, S., Mahato, D. K., Chandra, P., Hwang, S. K., Kumar, P., Huh, Y. S., & Han, Y.-K. (2018) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2018.06.011 · Cited by 463
Current applications of nanoparticles in infectious diseases
Zazo, H., Colino, C. I., & Lanao, J. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.008 · Cited by 434
Yeh, Y.-C., Huang, T.-H., Yang, S.-C., Chen, C.-C., & Fang, J.-Y. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00286 · Cited by 416
Liu, Y., Busscher, H. J., Zhao, B., Li, Y., Zhang, Z., van der Mei, H. C., Ren, Y., & Shi, L. (2016) · ACS Nano · doi:10.1021/acsnano.6b01370 · Cited by 379
Nanomedicine in the management of microbial infection – Overview and perspectives
Zhu, X., Radovic-Moreno, A. F., Wu, J., Langer, R., & Shi, J. (2014) · Nano Today · doi:10.1016/j.nantod.2014.06.003 · Cited by 362
Antibacterial activity of graphene-based materials
Szunerits, S., & Boukherroub, R. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb01647b · Cited by 327
Gao, L., Liu, Y., Kim, D., Li, Y., Hwang, G., Naha, P. C., Cormode, D. P., & Koo, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.051 · Cited by 324
Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections
Ma, Y., Wang, C., Li, Y., Li, J., Wan, Q., Chen, J., Tay, F. R., & Niu, L. (2020) · Advanced Science · doi:10.1002/advs.201901872 · Cited by 314
Nanotechnology-based drug delivery systems for control of microbial biofilms: a review
Dos Santos Ramos, M. A., Da Silva, P., Spósito, L., De Toledo, L., Bonifácio, B., Rodero, C. F., Dos Santos, K., Chorilli, M., & Bauab, T. M. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s146195 · Cited by 277
Infection microenvironment-related antibacterial nanotherapeutic strategies
Wang, Z., Liu, X., Duan, Y., & Huang, Y. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2021.121249 · Cited by 268
Nafee, N., Husari, A., Maurer, C. K., Lu, C., de Rossi, C., Steinbach, A., Hartmann, R. W., Lehr, C.-M., & Schneider, M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.055 · Cited by 208
“Apart from themetallic nanoparticles exerting their own antimicrobial action, special attention to lipid and polymeric nanocarriers is currently growing due to their attractive properties like biocompatibility, versatility of materials and surface modifications, possibility for targeting and triggered release, ability…”
BackgroundShaaban, M. I., Shaker, M. A., & Mady, F. M. (2017) · Journal of Nanobiotechnology · doi:10.1186/s12951-017-0262-9 · Cited by 58
Metadata
- Authors
- Forier, K., Raemdonck, K., De Smedt, S. C., Demeester, J., Coenye, T., & Braeckmans, K.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 190
- Pages
- 607-623
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W1998624315
- Cited by
- 464
- References
- 108
- FWCI
- 10.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.